➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKesson
McKinsey
AstraZeneca
Moodys

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 9,085,627

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,085,627
Title:Expression system with SAR element from IFN.alpha.2
Abstract: A short human genomic nucleotide sequence from the SAR3 region of the human interferon .alpha.2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.
Inventor(s): Durocher; Yves (Quebec, CA)
Assignee: National Research Council of Canada (Ottawa, Ontario, unknown)
Application Number:14/110,944
Patent Claims:see list of patent claims

Details for Patent 9,085,627

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial National Research Council of Canada (Ottawa, Ontario, unknown) 2031-04-13 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial National Research Council of Canada (Ottawa, Ontario, unknown) 2031-04-13 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial National Research Council of Canada (Ottawa, Ontario, unknown) 2031-04-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Express Scripts
Moodys
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.